Next Generation Therapeutic Laser Receives Safety Approval
We will be having the Theralase CEO and President Roger White on the weekend show. Please leave any questions you have for Roger in the comment section.
Toronto, Ontario – June 10, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that its next generation therapeutic laser, the TLC-2000, has recently received safety approval from the Canadian Standards Association (“CSA”).
CSA conducted an in-depth review of the Company’s technical testing results and approved the product in accordance with the latest international medical standards, including Canadian and US standards. The CSA safety approval paves the way for formal Health Canada approval anticipated in early July 2015.
The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology “senses” the exact location of injured tissue in a body and then automatically adjusts for a patient’s physical characteristics to deliver an optimized dose of laser light energy to heal the injury faster and more effectively than any other laser product on the market.
Roger Dumoulin-White, President and CEO of Theralase stated that, “In order to develop cutting edge technology that is superior to any existing technology on the market and in the process creating a new industry standard takes: vision, knowledge, perseverance, capital and luck. Thankfully, Theralase was blessed to have all five in the creation of the next generation TLC-2000 therapeutic laser system over the last few years. I join my entire organization into welcoming the debut of the next generation cold laser therapy product to Canadian healthcare practitioners within the next 30 days.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Pink®) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com .
Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO, Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
1.) Has TLT made a decision as to what the next cancer indication might be and any idea of timetable if so.
2.) Does TLT require the TLC-3000 device for ph1 bladder trial or can this intravesical treatment use prior art technology?
Thanks again Al!
Great questions so far guys. Stay tuned to Roger White’s interview on the weekend show.
Theralase announced preliminary results of the use of PDT in a rat model for destroying cancer last year in December. These results warranted further evaluating to confirm cancer destruction. No update was provided and continued study on control animals was needed to verify research. What is the update on these preliminary animal PDT studies? Did the animals develop an immune response to the cancer? Was there complete cancer destruction after further observations?
Great to know that the 2000 should be released soon. Please ask, as the previous posters mentioned, about the TLT 3000, and what might be required going into clinical trials later this year. There seems to be differing opinions on what the TLT 3000 really is, so it would be great for Roger to clarify its description and necessity for future trials and certifications for everyone. Also, their forecast of TLT 2000 revenue (assuming a July HC approval) would be great to know as well.
Thanks for getting Roger back on.
Has the immune memory response persisted in the larger-scale models of the toxicology trial?
TLC-3000;
What is it?
Does it need separate approval?
Will it be used in the upcoming Phase 1b/2a Trials?
Next round of financing to come for the Phase 2a trials?
Is the cost 15-25 million dollars?
Do you hope to have the Form 20-F completed and be listed on a proper US stock exchange such as Nasdaq and have a $2 to minimize shareholder dilution?
What is the status of the 8-Log kill bacteria division of TLT. Will this technology be developed by the growing asset base of the Laser division via TLC-2000 revenues?
General timeline concerns about Citox, JSS, Sigma and the process to filing the application forms to Health Canada?